The Pharmaceutical Research and Manufacturers of America (PhRMA) responded to an analysis comparing assessments by the Institute for Clinical and Economic Review's (ICER), warning that a one-size-fits-all framework would mean that 62 percent to 93 percent of patients with serious, complex conditions would face access barriers to treatment.